Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Metabolism and clinical pharmacokinetics of 2-methyl-n-(2'-(pyrrolidinyl-1-ylsulfonyl)-n-[1,1'-biphenyl]-4-yl)propran-1-amine: insights into monoamine oxidase- and CYP-mediated disposition by integration of in vitro ADME tools.

Sawant Basak A, Byon W, Tseng-Lovering E, Funk C, Wood L, Lin C, Delnomdedieu M, Verhoest P, Parikh V, Cox LM, Miller E, Gao H, Obach RS.

Xenobiotica. 2014 May;44(5):438-54. doi: 10.3109/00498254.2013.850552. Epub 2013 Dec 4.

PMID:
24304147
2.

Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.

Shen HW, Wu C, Jiang XL, Yu AM.

Biochem Pharmacol. 2010 Jul 1;80(1):122-8. doi: 10.1016/j.bcp.2010.02.020. Epub 2010 Mar 3.

3.

Characterization of 1-Aminobenzotriazole and Ketoconazole as Novel Inhibitors of Monoamine Oxidase (MAO): An In Vitro Investigation.

Shaik AN, LeDuc BW, Khan AA.

Eur J Drug Metab Pharmacokinet. 2017 Oct;42(5):827-834. doi: 10.1007/s13318-017-0401-6.

PMID:
28185143
5.

In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human.

Erickson DA, Hollfelder S, Tenge J, Gohdes M, Burkhardt JJ, Krieter PA.

Drug Metab Dispos. 2007 Dec;35(12):2232-41. Epub 2007 Sep 19.

PMID:
17881661
6.

Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients.

Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H.

Biochem Pharmacol. 2015 Jan 1;93(1):104-9. doi: 10.1016/j.bcp.2014.11.011. Epub 2014 Dec 2.

PMID:
25475885
7.
8.

Individual differences in in vitro and in vivo metabolic clearances of antipsychotic risperidone from Japanese subjects genotyped for cytochrome P450 2D6 and 3A5.

Okubo M, Morita S, Murayama N, Akimoto Y, Goto A, Yamazaki H.

Hum Psychopharmacol. 2016 Mar;31(2):93-102. doi: 10.1002/hup.2516. Epub 2016 Feb 8.

PMID:
26856541
9.

Reduction of site-specific CYP3A-mediated metabolism for dual angiotensin and endothelin receptor antagonists in various in vitro systems and in cynomolgus monkeys.

Zhang H, Zhang D, Li W, Yao M, D'Arienzo C, Li YX, Ewing WR, Gu Z, Zhu Y, Murugesan N, Shyu WC, Humphreys WG.

Drug Metab Dispos. 2007 May;35(5):795-805. Epub 2007 Feb 15.

PMID:
17303626
10.

Monoamine oxidase B oxidizes a novel multikinase inhibitor KW-2449 to its iminium ion and aldehyde oxidase further converts it to the oxo-piperazine form in human.

Hosogi J, Ohashi R, Maeda H, Tashiro S, Fuse E, Yamamoto Y, Kuwabara T.

Drug Metab Pharmacokinet. 2017 Oct;32(5):255-264. doi: 10.1016/j.dmpk.2017.06.002. Epub 2017 Jun 22.

PMID:
28751116
12.

Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.

Henderson CJ, McLaughlin LA, Scheer N, Stanley LA, Wolf CR.

Mol Pharmacol. 2015 Apr;87(4):733-9. doi: 10.1124/mol.114.097394. Epub 2015 Feb 5.

PMID:
25657337
13.

Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor.

Mosure KW, Knipe JO, Browning M, Arora V, Shu YZ, Phillip T, Mcphee F, Scola P, Balakrishnan A, Soars MG, Santone K, Sinz M.

J Pharm Sci. 2015 Sep;104(9):2813-23. doi: 10.1002/jps.24356. Epub 2015 Jan 28.

PMID:
25631585
14.

Metabolism of a 5HT6 Antagonist, 2-Methyl-1-(Phenylsulfonyl)-4-(Piperazin-1-yl)-1H-Benzo[d]imidazole (SAM-760): Impact of Sulfonamide Metabolism on Diminution of a Ketoconazole-Mediated Clinical Drug-Drug Interaction.

Sawant-Basak A, Obach RS, Doran A, Lockwood P, Schildknegt K, Gao H, Mancuso J, Tse S, Comery TA.

Drug Metab Dispos. 2018 Jul;46(7):934-942. doi: 10.1124/dmd.118.080457. Epub 2018 Apr 25.

PMID:
29695615
15.

The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro.

Zhan YY, Liang BQ, Li XY, Gu EM, Dai DP, Cai JP, Hu GX.

Xenobiotica. 2016;46(5):439-44. doi: 10.3109/00498254.2015.1088175. Epub 2015 Sep 22.

PMID:
26391142
16.

Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242).

Verhoest PR, Basak AS, Parikh V, Hayward M, Kauffman GW, Paradis V, McHardy SF, McLean S, Grimwood S, Schmidt AW, Vanase-Frawley M, Freeman J, Van Deusen J, Cox L, Wong D, Liras S.

J Med Chem. 2011 Aug 25;54(16):5868-77. doi: 10.1021/jm2006035. Epub 2011 Jul 22.

PMID:
21744827
17.

Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.

Belmonte C, Ochoa D, Román M, Saiz-Rodríguez M, Wojnicz A, Gómez-Sánchez CI, Martín-Vílchez S, Abad-Santos F.

Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):596-605. doi: 10.1111/bcpt.12960. Epub 2018 Feb 22.

18.

Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.

Lalovic B, Phillips B, Risler LL, Howald W, Shen DD.

Drug Metab Dispos. 2004 Apr;32(4):447-54.

PMID:
15039299
19.

Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.

Sharma R, Sun H, Piotrowski DW, Ryder TF, Doran SD, Dai H, Prakash C.

Drug Metab Dispos. 2012 Nov;40(11):2143-61. doi: 10.1124/dmd.112.047316. Epub 2012 Aug 15.

PMID:
22896728
20.

Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator.

Jornil J, Jensen KG, Larsen F, Linnet K.

Drug Metab Dispos. 2010 Mar;38(3):376-85. doi: 10.1124/dmd.109.030551. Epub 2009 Dec 10.

PMID:
20007670

Supplemental Content

Support Center